Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial

JAMA

Volumn 282, Issue 20, 1999, Pages 1921-1928

  Simon, Lee S ^a   Weaver, Arthur L ^b   Graham, David Y ^b   Kavitz, Alan J ^b   Lipsky, Peter E ^b   Hubbard, Richard C ^b   Isakson, Peter C ^b   Verburg, Kenneth M ^b   Yu, Shawn S ^b   Zhao, William W ^b   Geis, G Steven ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CELECOXIB; CORTICOSTEROID; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NAPROXEN; PREDNISONE;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EDEMA; ENZYME INHIBITION; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; UPPER GASTROINTESTINAL TRACT; UPPER RESPIRATORY TRACT INFECTION;

EID: 0033601089     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.20.1921     Document Type: Article

References (53)

1. Vane JR, Botting RM. Biological properties of cyclooxygenase products. In: Lipid Mediators. London, England: Academic Press Ltd; 1994:61-97.
2. Abramson SR, Weissman G. The mechanisms of action of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1989;32:1-9.
3. Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol. 1996;62: 167-215.
4. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS 10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem. 1992; 267:7991-7994.
5. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A. 1991;88:2692-2696.
6. O'Neill GP, Ford-Hutchinson AW. Expression of messenger mRNA for cydooxgenase-1 and cydooxygenase-2 in human tissues. FEBS Lett. 1993;330:156-160.
7. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, monkey, and human gastrointestinal tracts. Gastroenterology. 1996;111:445-454.
8. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994;91:12013-12017.
9. Fu J-Y, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737-16740.
10. Crofford LJ, Wilder RL, Ristimäki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1, phorbol ester, and corticosteroids. J Clin Invest. 1994;93:1095-1101.
11. DuBois RN, Awad J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor and phorbol ester. J Clin Invest. 1994;93:493-498.
12. Raz A, Wyche A, Siegel N, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci U S A. 1989;86: 1657-1661.
13. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest. 1990;86:1375-1379.
14. O'Banion MK, Sadowski HB, Winn V. A serumand glucocorticoid-regulated 4 kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 1991;266:23261-23267.
15. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and inducible forms of human cydooxygenase. Biochem J. 1995;305:479-484.
16. Futaki N, Arai I, Hamasaki S, Takahashi S, Higuchi S, Otomo S. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenanair-pouch inflammation. J Pharm Pharmacol. 1992; 45:753-755.
17. Chan C, Boyce S, Brideau C, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in ratand nonhuman primate stomach. J Pharmacol Exp Ther. 1995;274:1531-1537.
18. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 5C-58635 (celecoxib). J Med Chem. 1997;40:1347-1365.
19. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta analysis. Ann Intern Med. 1991;115:787-796.
20. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ. 1997;315:1333-1337.
21. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology. 1993;105:1078-1088.
22. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257-263.
23. Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, Geis GS. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers: a one-year study. Dig Dis Sci. 1995;40:1125-1131.
24. Roth SH, Bennett RE, Caldron PH, Mitchell CS, Swenson CM. Endoscopic evaluation of the long-term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clin Drug Invest. 1995;9:171-179.
25. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996;334:1435-1439.
26. Cheatum DE, Arvanitakis C, Gumpel M, et al. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999;21:992-1003.
27. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
28. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993;119:257-262.
29. Anderson GD, Hauser SD, McGarity KL, et al. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996; 97:2672-2679.
30. Masferrer J, Zweifel B, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci U S A. 1994;91:3228-3232.
31. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum. 1998; 41:1591-1602.
32. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
33. Hochberg MC, Chang RW, Dwosh I, Linsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498-502.
34. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee: validation: value in comparison with other assessment tests. Scand J Rheumatol. 1987;65(suppl):85-89.
35. Langley GB, Sheppard H. Problems associated with pain measurement in arthritis: comparison of visual analogue and verbal rating scales. Clin Exp Rheumatol. 1984;2:231-234.
36. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis trials. Arthritis Rheum. 1993;36:729-740.
37. Egger MJ, Huth DA, Ward JR, Reading JC, Williams HJ. Reduced joint count indices in the evaluation of rheumatoid arthritis. Arthritis Rheum. 1985;28:613-619.
38. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford health assessment questionnaire functional disability index in patients with rheumatoid arthritis. J Rheumatol. 1988;15:1480-1488.
39. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75: 800-802.
40. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-735
41. Masferrer JL, Reddy ST, Zweifel BS, et al. In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther. 1994;270:1340-1344.
42. Crofford LJ, Wilder RL, Ristimãki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Biol Chem. 1990;265:16737-16740.
43. Gall EP, Caperton EM, McComb JE, et al. Clinical comparison of ibuprofen, fenoprofen calcium, naproxen and tolmetin sodium in rheumatoid arthritis. J Rheumatol. 1982;9:402-407.
44. Day RO, Furst DE, Dromgoole SH, Kamm B, Roe R, Paulus HE. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clin Pharmacol Ther. 1982;31:733-740.
45. Shoen RT, Vender RJ. Mechanisms of nonsteroidal antiinflammatory drug-induced gastric damage. Am J Med. 1989;86:449-458.
46. Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastroenterology. 1989;96:675-681.
47. Shorrock CJ, Rees WDW. Overview of gastroduodenal mucosal protection. Am J Med. 1988;84 (suppl 2a):25-34.
48. Soil AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal antiinflammatory drugs and peptic ulcer disease. Ann Intern Med. 1991;114:307-319.
49. Akdamar K, Ertan A, Agrawal NM, et al. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc. 1986;32:78-80.
50. Ihmaki T, Varis K, Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Scand J Gastroenterol. 1979;14:801-812.
51. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of pepticulcer disease. BMJ. 1995;310:827-830.
52. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol. 1996;91:2080-2086.
53. Wilske KR, Healey LA. Remodeling the pyramid: a concept whose time has come. J Rheumatol. 1989; 16:565-567.